Applied Genetic Technologies Corp (AGTC) announced its most recent quarterly financial results on Monday, Sep-12-2016. AGTC said it had a profit of $0.15 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.07. Analysts had a consensus of $0.08. The company posted revenue of $12.10 million in the period, compared to analysts expectations of $13.09 million. AGTC’s revenue was up 1604.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.48 EPS.
Applied Genetic Technologies Corp opened for trading at $12.88 and hit $13.35 on the upside on Wednesday, eventually ending the session at $13.01, with a gain of 1.25% or 0.16 points. The heightened volatility saw the trading volume jump to 101,707 shares. Company has a market cap of $235 M.
In a different news, on Jan 26, 2015, Daniel L Menichella (V.P. & Chief Business Officer) sold 1,996 shares at $24.90 per share price.
Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1) a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis an inherited condition causing early blindness. Its products also used to treat X-linked retinoschisis an inherited form of retinal degeneration affecting young males with poor vision either in infancy or at school age; and achromatopsia an inherited condition that is associated with color blindness visual acuity loss and extreme light sensitivity resulting in daytime blindness.